{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:43Z","timestamp":1790384323473,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00985-1","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:25:25Z","timestamp":1784096725000},"page":"2659-2670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Intermittent Negative Pressure Treatment on Spasticity and Spasticity-Related Symptoms in Patients with Multiple Sclerosis: A Two-Arm Randomized Trial"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-9841","authenticated-orcid":false,"given":"Jesper","family":"N\u00f8rregaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacob","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kierkegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blinkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"985_CR1","unstructured":"Multiple Sclerosis International Federation \u2013 Atlas of MS 2024 (3rd Edition)."},{"issue":"3","key":"985_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology."},{"issue":"2","key":"985_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med."},{"issue":"5","key":"985_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","volume":"10","author":"MA Rizzo","year":"2004","unstructured":"Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589\u201395.","journal-title":"Mult Scler."},{"key":"985_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fneur.2010.00149","volume":"1","author":"A Mukherjee","year":"2010","unstructured":"Mukherjee A, Chakravarty A. Spasticity mechanisms\u2014for the clinician. Front Neurol. 2010;1:149.","journal-title":"Front Neurol."},{"issue":"3","key":"985_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.12202","volume":"129","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis\u2013clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154\u201362.","journal-title":"Acta Neurol Scand."},{"key":"985_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jocn.2017.02.044","volume":"39","author":"A Naro","year":"2017","unstructured":"Naro A, Leo A, Russo M, et al. Breakthroughs in the spasticity management: Are non-pharmacological treatments the future? J Clin Neurosci. 2017;39:16\u201327.","journal-title":"J Clin Neurosci."},{"issue":"11","key":"985_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/1352458516643600","volume":"22","author":"S Otero-Romero","year":"2016","unstructured":"Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016;22(11):1386\u201396.","journal-title":"Mult Scler."},{"issue":"11","key":"985_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/PHM.0000000000000970","volume":"97","author":"M Etoom","year":"2018","unstructured":"Etoom M, Khraiwesh Y, Lena F, et al. Effectiveness of physiotherapy interventions on spasticity in people with multiple sclerosis: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2018;97(11):793\u2013807.","journal-title":"Am J Phys Med Rehabil."},{"issue":"5","key":"985_CR10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.jvs.2020.10.024","volume":"73","author":"H Hoel","year":"2021","unstructured":"Hoel H, Pettersen EM, H\u00f8iseth L, et al. A randomized controlled trial of treatment with intermittent negative pressure for intermittent claudication. J Vasc Surg. 2021;73(5):1750-8.e1.","journal-title":"J Vasc Surg."},{"key":"985_CR11","doi-asserted-by":"crossref","unstructured":"Norborg H, Haugstad R, Hoel H, Mathiesen I, Myhr K-M. ECTRIMS 2022 \u2013 ePoster: a single center, open, non-controlled pilot investigation to evaluate the effects of intermittent negative pressure on spasticity and concomitant pain in patients with multiple sclerosis. Multiple Scler J. 2022;28(3_suppl):692\u2013945.","DOI":"10.1177\/13524585221123682"},{"key":"985_CR12","doi-asserted-by":"crossref","unstructured":"Fortes G, Hoel H, Mathiesen I. ECTRIMS 2022 \u2013 ePoster: Intermittent negative pressure applied to the lower limb of patients with multiple sclerosis and its impact on symptoms. Multiple Scler J. 2022;28(3_suppl):692\u2013945.","DOI":"10.1177\/13524585221123682"},{"issue":"2","key":"985_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol."},{"issue":"20","key":"985_CR14","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14241","volume":"7","author":"H Hoel","year":"2019","unstructured":"Hoel H, H\u00f8iseth L\u00d8, Sandb\u00e6k G, et al. The acute effects of different levels of intermittent negative pressure on peripheral circulation in patients with peripheral artery disease. Physiol Rep. 2019;7(20):e14241.","journal-title":"Physiol Rep."},{"issue":"11","key":"985_CR15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology."},{"issue":"2","key":"985_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","volume":"67","author":"RW Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206\u20137.","journal-title":"Phys Ther."},{"issue":"6","key":"985_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jpainsymman.2010.08.016","volume":"41","author":"MJ Hjermstad","year":"2011","unstructured":"Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073\u201393.","journal-title":"J Pain Symptom Manage."},{"issue":"Pt 5","key":"985_CR18","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962\u201373.","journal-title":"Brain."},{"issue":"5","key":"985_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","volume":"23","author":"RW Motl","year":"2017","unstructured":"Motl RW, Cohen JA, Benedict R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):704\u201310.","journal-title":"Mult Scler."},{"issue":"4","key":"985_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7224\/1537-2073.2017-046","volume":"20","author":"DA Scalzitti","year":"2018","unstructured":"Scalzitti DA, Harwood KJ, Maring JR, et al. Validation of the 2-minute walk test with the 6-minute walk test and other functional measures in persons with multiple sclerosis. Int J MS Care. 2018;20(4):158\u201363.","journal-title":"Int J MS Care."},{"key":"985_CR21","unstructured":"Scalia M, Borriello G, Mathiesen I, Hoel H, Macaluso A, editors. Intermittent negative pressure reduces spinal excitability in multiple sclerosis: neurophysiological evidence from soleus h-reflex modulation. RiMS; 2026; Prague."},{"issue":"1","key":"985_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5114\/pq.2020.102165","volume":"30","author":"O Bacca","year":"2022","unstructured":"Bacca O, Pati\u00f1o-Segura MS, Herrera E. Circumferential pressure treatment reduces post-stroke spasticity: a pilot randomized controlled trial. Physiother Quart. 2022;30(1):39\u201345.","journal-title":"Physiother Quart."},{"issue":"8","key":"985_CR23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0003-9993(96)90256-7","volume":"77","author":"JA Robichaud","year":"1996","unstructured":"Robichaud JA, Agostinucci J. Air-splint pressure effect on soleus muscle alpha motoneuron reflex excitability in subjects with spinal cord injury. Arch Phys Med Rehabil. 1996;77(8):778\u201382.","journal-title":"Arch Phys Med Rehabil."},{"issue":"8","key":"985_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0895-4356(00)00206-7","volume":"53","author":"TJ Kaptchuk","year":"2000","unstructured":"Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have enhanced placebo effects? J Clin Epidemiol. 2000;53(8):786\u201392.","journal-title":"J Clin Epidemiol."},{"key":"985_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081079","author":"JS Hansen","year":"2023","unstructured":"Hansen JS, Gustavsen S, Roshanisefat H, et al. Cannabis-based medicine for neuropathic pain and spasticity-a multicenter, randomized, double-blinded, placebo-controlled trial. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16081079.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"985_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","volume":"68","author":"RA Moore","year":"2013","unstructured":"Moore RA, Straube S, Aldington D. Pain measures and cut-offs - \u201cno worse than mild pain\u201d as a simple, universal outcome. Anaesthesia. 2013;68(4):400\u201312.","journal-title":"Anaesthesia."},{"issue":"12","key":"985_CR27","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","volume":"156","author":"AH Tuttle","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015;156(12):2616\u201326.","journal-title":"Pain"},{"issue":"10","key":"985_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11910-019-0991-2","volume":"19","author":"CL Hugos","year":"2019","unstructured":"Hugos CL, Cameron MH. Assessment and measurement of spasticity in MS: state of the evidence. Curr Neurol Neurosci Rep. 2019;19(10):79.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"9","key":"985_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/0269215517745349","volume":"32","author":"PW Kwong","year":"2018","unstructured":"Kwong PW, Ng GY, Chung RC, Ng SS. Transcutaneous electrical nerve stimulation improves walking capacity and reduces spasticity in stroke survivors: a systematic review and meta-analysis. Clin Rehabil. 2018;32(9):1203\u201319.","journal-title":"Clin Rehabil."},{"issue":"4","key":"985_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1352458506071509","volume":"13","author":"L Miller","year":"2007","unstructured":"Miller L, Mattison P, Paul L, Wood L. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler. 2007;13(4):527\u201333.","journal-title":"Mult Scler."},{"key":"985_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.msard.2017.06.013","volume":"17","author":"R Ehling","year":"2017","unstructured":"Ehling R, Edlinger M, Hermann K, et al. Successful long-term management of spasticity in patients with multiple sclerosis using a software application (APP): a pilot study. Mult Scler Relat Disord. 2017;17:15\u201321.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"985_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149\u201358.","journal-title":"Pain."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00985-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:02:40Z","timestamp":1790380960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00985-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fredrik Piehl has received research grants from Janssen, Merck KGaA and UCB, and fees for serving on DMCs in clinical trials with Chugai, Lundbeck and Roche, and preparation of expert witness statement for Novartis. Marie Kierkegaard has received honoraria for lectures from Merck and Novartis. Kjell Morten Myhr has received speaker honoraria from Biogen, Sanofi and Novartis, and honoraria for participation in a scientific advisory board from Alexion, and has participated in clinical trials organized by Biogen, Merck, Novartis, Otivio, Sanofi and Roche. Jesper N\u00f8rregaard has received speaker honoraria from Merck, Sanofi and Novartis, and honoraria for participation in scientific advisory boards from Merck and Sanofi. Iacob Mathiesen and Henrik Hoel are shareholders and employees of Otivio AS. Iacob Mathiesen and Henrik Hoel have stock options and are inventors of multiple Otivio patents. Sarah Haghighi and Morten Blinkenberg have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Committees for Medical and Health Research Ethics in Norway (reference no. 503097), Sweden (reference no. 2022-069904-02) and Denmark (reference no. 2208607). Written informed consent was obtained from all patients before inclusion. All procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the appropriate institutional committees. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Approval of the investigation was given by the Independent Ethics Committee (IEC), and a favorable opinion was given by the Competent Authority (CA) in each participating country. Initial approval was obtained for clinical investigation plan number FO-NP-002, CIP version 5.1, 25-04-2023 (Sweden, Denmark), FO-NP-002, CIP version Norway 4.3,31-05-2023 (Norway). The approvals were obtained as follows: Sweden \u2013 27 June 2022 IEC, 15 June 2022 CA; Denmark \u2013 13 July 2022 IEC, 8 August 2022 CA; Norway \u2013 3 February 2023 IEC Conditional approval of main part only, 05 May 2023 IEC OEP part, 16 September 2022 CA.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}